Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

ASCO Offers Stage For New Data For CAR-T And ADC Candidates

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

Long red ladder to goal target the business concept on blue pastel color background with shadows 3D rendering
New data support multiple candidates aimed at the target • Source: Shutterstock

GlaxoSmithKline PLC may win the race to bring a BCMA-targeting treatment for multiple myeloma to the market this year, but CAR-T therapies from Bristol-Myers Squibb Co./bluebird bio Inc. and Janssen Pharmaceutical Cos./Legend Biotech Corp. are close behind. While all three are effective in heavily pre-treated patients, the companies developing them are pursuing combination regimens and moving into earlier stages of the disease to raise the bar in myeloma treatment.

Updated clinical trial results for GSK’s belantamab mafodotin, an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) were presented a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

 
• By Alexandra Shimmings

AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    

ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

 
• By Alexandra Shimmings

Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.    

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.